Evidence map›Paper›PMID 40487645›Full record

ArticleActa pharmaceutica Sinica. B2025

A proximity-induced chimera platform for targeted protein arginine methylation.

Yanlin Jian, Tianyang Zhou, Chendong Guo, Yibo Gao, Chen Yao, Zixi Wang, Xuehan Jiang, Ke Wang, Jian Ma, Yang Gao and 4 more

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yanlin JianDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Tianyang ZhouDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Chendong GuoDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yibo GaoDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Chen YaoDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Zixi WangDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Xuehan JiangDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Ke WangDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Jian MaDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yang GaoDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yizeng FanDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Jing LiuDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Bohan MaDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Lei LiDepartment of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arginine methylation is a critical post-translational modification that plays multifaceted biological functions. However, the manipulation of protein arginine methylation largely depends on genetic or pharmaceutic inhibition of the regulatory enzymes, protein arginine methyltransferases (PRMTs), or non-methylation substitution of corresponding arginine residue to lysine or alanine of protein of interest (POI), which inevitably affects other substrates, or disrupts the structure of POI. Thus, it urges an approach to specifically modulate the arginine methylation of a POI under physiological conditions. To this end, we report the discovery of a methylation tagging system (MeTAG), that enables targeted modification of protein arginine methylation. Through bridging the methyltransferase PRMT5 proximity to a POI, MeTAG facilitates the arginine methylation of POIs, including known arginine methylated proteins, androgen receptor (AR) and protein kinase B (AKT), as well as a neo-substrate E1A binding protein (p300), in a reversible and PRMT5-dependent manner. Moreover, MeTAG can regulate downstream signaling in a methylation dependent manner, leading to downregulation of

Indexed as

AKTAndrogen receptorArginine methylationBifunctional moleculesMethylation tagging systemP300Protein arginine methyltransferasesTernary complex

Identifiers

PMID40487645
PMCPMC12145041

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.